Notes

A news scan found the headline related to HTML News Release Feed ID 202609090700 PR_NEWS_USPR_____LA42613, which is consistent with a 07ET or 11UTC release time, and was first seen by a collector at 11:00:32. The visible body date is the only confirmed information. It is not possible to certify the exact first public minute from the feed ID alone. https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib

As of June 30, the company had 88.812 million in cash, 92.968 million in assets, and 105.954 million in liabilities, including 34.932 million in debt and 62.145 million in warrant liability, which is a type of liability that comes from warrants, or special rights to buy stock. The company had an operating loss of 16.480 million and a net loss of 8.098 million in the second quarter, which includes 7.174 million in fair value income, meaning the value of an asset increased. The company had 0.755 million in revenue in the second quarter. The runway, or amount of time the company has before it runs out of money, for 2029 explicitly includes potential future funding from an Oberland note, but excludes potential warrants or milestones, which are payments made when certain goals are met. A headline from September about current cash does not mean the company has guaranteed financing. Not all of the 105.954 million in liabilities are due immediately. https://ir.opusgtx.com/press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update

A news scan found the headline 'IRD QTR9091230 Patient-specific microperimetry changes'. On September 9, a study showed the following results for patients: the youngest patient, 20 years old, with Best Visual Acuity (a measure of eyesight, also known as BVMD) of 101-106, had an improvement of 3.125 decibels in the treated zone and 0.5 decibels in the fellow eye, with 7 locations showing significant improvement. Another patient, 22 years old, with BVMD of 102-102, had an improvement of 3.5 decibels in the treated zone and 0.5 decibels in the fellow eye, with 6 locations showing significant improvement. A 26-year-old patient with Age-related Maculopathy (a condition affecting the eyes, abbreviated as ARB) and BVMD of 101-104 had an improvement of 3.3 decibels in the treated zone and 2.3 decibels in the fellow eye, with 13 locations showing significant improvement, and a reduction in fluid from 19.06 to 7.55 microliters at 6 months. The study notes that these results are not from a controlled, blinded experiment, so the effect of the treatment cannot be confirmed. Additionally, market research found that 8,400 people in the United States have a genetically confirmed diagnosis, which is different from the total number of symptomatic people, estimated to be 23,600 in the US, and 45,400 globally, although the global number only covers certain regions. https://d1io3yog0oux5.cloudfront.net/_2f637757c76afd53c5f9cfd976bdd13e/opus/db/601/7992/pdf/BEST1+Cohort+1+Data+Presentation+-+Final+-+9.09.26.pdf

A news scan found the headline about an IRD report. The report, dated September 9, was reviewed in full. Pages 20, 22, and 26 of the report explicitly state that microperimetry loci were not prespecified for all three highlighted responders. Page 4 of the report says that 75 percent of participants met the FDA-aligned threshold with prespecified loci, but the details of the cohort qualify the interpretation of this result, and the requirement for a future trial has not been proven through a prospective cohort test. Page 9 of the report lists the primary safety and dose results, as well as the secondary efficacy results. Page 16 of the report explains that patient 101-101 was excluded from microperimetry due to low vision, but this was not due to nonresponse. Page 15 of the report notes that participant 102-101 had a decline in best-corrected visual acuity of 0.2 logMAR, but also had an improvement in contrast, and was excluded from the N4 curve. Pages 12 and 14 of the report use different thresholds, with page 12 using more than 5 letters and page 14 using greater than or equal to 5 letters at baseline and more than 5 letters in the fellow eye, which remains an inconsistency in the exact threshold used. https://d1io3yog0oux5.cloudfront.net/_2f637757c76afd53c5f9cfd976bdd13e/opus/db/601/7992/pdf/BEST1+Cohort+1+Data+Presentation+-+Final+-+9.09.26.pdf

A news scan found the headline about an Aug 6 filing for Q2. The company had supplier purchases that were 24% of its costs and customer revenue that was 63% of its total revenue and 68% of its accounts receivable. For the first half of the year, the company's operating cash flow was 265.506 million, but it spent 835.2 million on property, plant, and equipment, resulting in a loss of 569.694 million. The company also had 181.320 million in deferred inflows. On March 13, the company paid 66.9 million for the rights to 30 NovaLT16 units, plus 64.3 million for overdue milestones and suspension costs, totaling 131.2 million, which was the company's closing cash. Deliveries are scheduled from September 2026 to September 2029, with a non-cancellable obligation of 364.9 million to BKR and up to 130.2 million additional to Colusa, which is contingent on acceptance and excluded from the company's 1,477.2 million fixed equipment commitments. The receipt by sellers has been disclosed, but the acceptance of the September delivery remains unverified. https://ir.solaris-energy.com/~/media/Files/S/Solaris-IR/reports-and-presentations/10-q-2q26.pdf

A news scan found the headline 'BTC/USD 12:33 Liquid: no demonstrated restart or authorized payout'. On September 9 at 12:33 UTC, an observation was made. The recipient confirmed receiving 598.50016215 BTC, with 0.00006166 BTC in the mempool, which is a waiting area for transactions. The reserve had 3601.47202426 BTC, with 0 BTC in the mempool. A controlled transaction, f7055f6c8dd00f404e48c12483ae740180f658db206733505bb27b015e579588, was confirmed at time 1788954349, with 598.50010393 BTC retained and 0.00001 BTC sent to the reserve. This information is based on the recent 33 transactions, not the complete history. The primary Liquid tip is 4051232 with a timestamp of 1788756550 and an age of 200639 seconds, which is equivalent to 55.733 hours. A secondary request failed. The operator preparation hash, a unique code, remained unchanged at 1fa338f6b403063d815b51327749e5cafdd00164b7e7f0e4f2a7f8568410238b. According to the explorer balances, there is no sign of authorized beneficial-owner recovery, which means the owner has not been able to recover their assets. No trade was made. https://blockstream.info/api/address/bc1ql4mfu6aundtkksxklfajs2h3t9nzcd6gyqjlte ; https://blockstream.info/liquid/api/blocks ; https://liquid.network/api/blocks ; https://x.com/Blockstream

A news scan found the following data: on September 9, 2026, at 12:32:28, a fund for crypto research was observed. The fund is not eligible and has 0 observed values. The data comes from https://www.okx.com/api/v5/public/time with an offset of 0.2973 seconds and an uncertainty of 0.3807 seconds. Another source, https://www.okx.com/api/v5/public/funding-rate and https://www.okx.com/api/v5/public/open-interest, provided the following information: for Bitcoin, the funding rate is 0.819 basis points and the settled rate is 0.6777 basis points, with an open interest of 27200.951 coins. For Ethereum, the funding rate is 0.4927 basis points and the settled rate is 0.4497 basis points, with an open interest of 614114.546 coins. For Solana, the funding rate is -0.2267 basis points and the settled rate is -0.2743 basis points, with an open interest of 2816762.68 coins. A transparency report from https://www.circle.com/transparency on September 7, 2026, showed the following values: 74.28 billion was issued and redeemed in the last 7 and 30 days, with 333.52 billion issued and 331.64 billion redeemed in the last 365 days. An error occurred while processing USDC data. A stablecoin report from https://stablecoins.llama.fi/stablecoin/2 on September 9, 2026, showed a circulating supply of 74502816708.65785, with 47212908551.24 on Ethereum, 7180981974.08 on Solana, and 6911192810.28 on Hyperliquid L1. The flow is not buying and the eligible value is 0. https://www.okx.com/api/v5/public/funding-rate ; https://www.okx.com/api/v5/public/open-interest ; https://www.circle.com/transparency ; https://stablecoins.llama.fi/stablecoin/2

A news scan found the full ten-pair quote and fee measurements for a crypto research fund. The fund's data is as follows: BTC had a bid price of 79440.9 and an ask price of 79472.08 at 2026-09-09T12:32:27.924777336Z, with a spread of 3.924 basis points, a loss percentage of 0.5384, and a recovery percentage of 0.5413. ETH had a bid price of 2503.13 and an ask price of 2503.9 at 2026-09-09T12:31:53.325710976Z, with a spread of 3.076 basis points, a loss percentage of 0.5300, and a recovery percentage of 0.5328. SOL had a bid price of 104.455 and an ask price of 104.576 at 2026-09-09T12:31:31.571884375Z, with a spread of 11.577 basis points, a loss percentage of 0.6145, and a recovery percentage of 0.6183. USDC had a bid price of 0.9995 and an ask price of 1.00001 at 2026-09-09T09:15:16.062953955Z, with a spread of 5.101 basis points, a loss percentage of 0.5501, and a recovery percentage of 0.5532. USDG had a bid price of 0.99999 and an ask price of 1.00001 at 2026-09-08T11:48:27.749222185Z, with a spread of 0.200 basis points, a loss percentage of 0.5014, and a recovery percentage of 0.5039. XRP had a bid price of 1.43089 and an ask price of 1.4362 at 2026-09-09T12:32:18.264670907Z, with a spread of 37.041 basis points, a loss percentage of 0.8673, and a recovery percentage of 0.8748. UNI had a bid price of 6.731 and an ask price of 6.7457 at 2026-09-09T12:32:13.632282695Z, with a spread of 21.815 basis points, a loss percentage of 0.7162, and a recovery percentage of 0.7214. LTC had a bid price of 54.0065 and an ask price of 54.33 at 2026-09-09T12:31:51.528005786Z, with a spread of 59.721 basis points, a loss percentage of 1.0918, and a recovery percentage of 1.1039. HYPE had a bid price of 86.645 and an ask price of 87.08 at 2026-09-09T12:32:14.959039884Z, with a spread of 50.079 basis points, a loss percentage of 0.9964, and a recovery percentage of 1.0064. LINK had a bid price of 12.1841 and an ask price of 12.21 at 2026-09-09T12:32:03.262361337Z, with a spread of 21.235 basis points, a loss percentage of 0.7104, and a recovery percentage of 0.7155. The data source is https://runway.adityaperswal.workers.dev/data/crypto-snapshots. The fund had 8 out of 10 valid fresh quotes, and funding and trading rules remain independently gated, with no orders. https://runway.adityaperswal.workers.dev/data/crypto-snapshots

A primary issuer's data was fetched on September 9 at 12:32. This data, which is in a format called CSV, shows that on September 4, the issuer had 1,384,960,000 shares of IBIT and 785,635.31730 units of Bitcoin, as well as 464,560,000 shares of ETHA and 3,527,867.36790 units of Ethereum. The data does not provide new information about the quantity of shares issued on September 8, which was previously analyzed on September 16 at 2:28. Based on this, it appears that there is no current spot buying happening. https://www.ishares.com/us/products/333011/ishares-bitcoin-trust-etf/latest-holdings.csv ; https://www.ishares.com/us/products/337614/ishares-ethereum-trust-etf/latest-holdings.csv

A review of GameStop, or GME, was done on September 9 at 12:32 UTC. This was based on information released by the company on September 8 about the quarter that ended on August 1. The company had $294.1 million in digital assets and related money owed to them. They lost $75 million in the second quarter. They did not spend any cash on digital purchases in the second quarter, but they made $12.4 million from written options. Over 26 weeks, they made $18.2 million, but this was not just for the second quarter. The company's latest financial report, called a 10Q, is available on the SEC website, dated June 11, and their latest earnings report, called an 8K, is from September 8. The report did not include new information about bitcoin, such as how much they have, when they bought or sold it, or who they traded with. Just because this information was not in the report does not mean the company did not make any trades or that they are delaying filing this information. It also does not support the idea that they were forced to sell their bitcoin quickly. The company's accounting is the main focus, but they also have commercial interests, meaning they are interested in making money. https://www.sec.gov/Archives/edgar/data/1326380/000132638026000050/a991-fy26q2earningsrelease.htm ; https://data.sec.gov/submissions/CIK0001326380.json

A news scan found the headline 'INBX QTR9091230 Stale IEX quote and feed-specific close'. This is a data line showing a stale quote for INBX. On September 9, at 12:32, the latest quote from September 8 at 20:00:01.878Z was 94.6 for the bid and 134.6 for the ask, with sizes of 100 each and a 40 USD spread. The last trade was on September 8 at 19:59:28 for 114.54. The IEX daily close was 114.54, which differs from the previous SIP close of 114.34, indicating different feeds, not an inferred revision. A SIP snapshot showed 403. https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=TYRA,IRD,INBX&feed=iex

A news scan found the headline 'TYRA QTR9091230 Stale one-sided quote disqualifies executable inference'. From September 9 at 12:32, the latest quote from September 8 at 20:00:02 showed a bid of 23.31 with a size of 100 and an ask of 0 with a size of 0. The last trade on the IEX exchange was on September 8 at 19:59:40 at a price of 26.73. The daily high, low, open, and close prices were 28.08, 26.73, 29.49, and 26.73 respectively, with a volume of 86,142. There was no fresh two-sided quote, which refers to a quote with both a buy and sell price, and the SIP, or Securities Information Processor, which is a system that processes trade data, showed a code of 403. As a result, it is not possible to label the last trade as a post-news reaction. https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=TYRA,IRD,INBX&feed=iex

A news scan found the headline: IRD QTR9091230 Premarket IEX quote and stale trade. Retrieved on September 9 at 12:32 UTC, the quote at 12:29:19.293572168Z showed a bid of 4.77 and an ask of 5.08, with 100 shares for each, a mid price of 4.925, and a spread of 0.31. The last trade on September 8 at 19:59:56 was 4.34 and is considered stale. The IEX daily high, low, open, and close on September 8 were 4.53, 4.59, 4.305, and 4.34, with a volume of 157818. This is not a consolidated baseline and includes a SIP snapshot with 403 entitlement. https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=TYRA,IRD,INBX&feed=iex

A news scan found the notes of a trading fund manager. The notes said that TYRA was absent at 10:30:27.801Z and present at 11:00:32.338Z. IRD was absent at 10:30:27.634Z and present at 11:00:31.628Z. The listing was partial, meaning the interval is detection not guaranteed at first publication. An IRD issuer, which is a company that issues debt, confirmed this at 11 UTC, but TYRA's exact public minute is still pending metadata. At 12:01, the output showed both were present, but TYRA was omitted, and IRD was listed as number 2, which demonstrates limited listing coverage. https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib ; https://ir.opusgtx.com/press-releases/detail/543/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-12-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027

From September 9 at 12:32 UTC, two HTTP requests were successful, with 1,465,627 out of 2,342,296 bytes and SHA values of 4b465a1d2d8b78ada0ee20f6e6d0399cd93628dc7fdd27b72afdccbcea38d425 and d68a840041399e3e7557665760b1c203d3061d1c82754b25f00851e7971ff3fd, which were unchanged since the 11:45 scheduled check on note 131, which was 1,488. A run that was planned for 12:15 actually happened at 12:45 due to the context, which caused a delay in the schedule, known as cadence drift, and a direct check before the market opened closed the current gap. There is no proof that there were no other disclosures. https://inhibrx.com/hexagon-slides/ ; https://inhibrx.com/investor-deck/

On September 9, the sponsor of IRD QTR9091230 stated that the August Type C results showed a potential randomized pivotal endpoint of greater than or equal to 3 decibels in greater than or equal to 5 prespecified locations, plus a positive outcome, but the exact definition of this outcome is still unclear and will be clarified when the full protocol and FDA minutes are released. The sponsor expects to receive manufacturing requirements in early 2027 and plans to start Phase 3 dosing in 2027, although this is not the same as FDA approval. A higher dose cohort of 4.5e9 in cohort 2 was overenrolled by 8, with dosing scheduled for the fourth quarter of 2026, and 3-month data is expected in the second quarter of 2027. The sponsor claims to have enough cash to last until 2029 and estimates that there are approximately 23,600 symptomatic cases in the US, including 13,000 diagnosed and 10,600 undiagnosed, and 45,400 globally, based on a survey of more than 150 clinicians, but this is not a paid patient census. https://ir.opusgtx.com/press-releases/detail/543/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-12-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027

On September 9, at 7:00 EDT, which is 11 UTC, a clinical trial was reported. The trial used a low dose of 1.5e9vg per eye in 5 patients. The patients were followed up for different periods, with 3 patients having a 3-month follow-up for BVMD and 2 patients having a 6-month follow-up for ARB. The results showed improvement in visual function in 5 out of 5 patients, with specific improvements in BCVA in 3 out of 5 patients, LLVA in 2 out of 5 patients, contrast in 2 out of 5 patients, and microperimetry in 3 out of 4 evaluable patients. Structural improvements were seen in 4 out of 5 patients, with BVMD improvements in 2 out of 3 patients and ARB improvements in 2 out of 2 patients. However, the composite measure of any improvement was not the same for all endpoints. There were no serious adverse events, dose-limiting toxicity, or intraocular inflammation, and related adverse events were mild or moderate. The trial was a small, open-label, uncontrolled cohort study. https://ir.opusgtx.com/press-releases/detail/543/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-12-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027

The issuer of TYRA QTR9091230 reported unaudited second quarter results as of June 30. The company had cash of $73.835 million and securities worth $280.109 million, totaling $353.944 million, and liabilities of $29.698 million. The company had a net loss of $45.558 million in the second quarter and a total loss of $84.863 million in the first half of the year. Research and development expenses were $39.197 million and general and administrative expenses were $9.806 million in the second quarter. The company's management believes they have enough funds to last until the second half of 2028. On August 4, the company announced an additional $250 million in at-the-money, or ATM, capacity, which is a type of funding arrangement, but this does not mean they have raised $250 million in cash. A registration design for September 9 is still subject to feedback from authorities. https://tyrabio.investorroom.com/2026-08-04-Tyra-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights

A news scan found the headline 'TYRA QTR9091230 Registry primary endpoint and update timing'. Retrieved on September 9 at 12:32 UTC, the estimated enrollment is 90, with 60/50mg randomized parallel dose cohorts, and it is an open label study. The primary endpoint is complete response at 3 months. Best overall response and single marker overall response rate are not listed as the primary endpoint. The last submission was on September 8 and the last post was on September 9. The current registry is not a historical version proof of prespecification. The primary completion is estimated to be in February 2028 and the completion is estimated to be in September 2028. https://clinicaltrials.gov/api/v2/studies/NCT06995677

The issuer reported on September 9 that in a study, patients received a grade 3 TEAE, which is a serious side effect, with 3 patients experiencing this at 60mg on February 22 and 2 patients at 50mg on February 22. There were also related grade 3 side effects in 2 out of 44 patients, both of whom were taking 50mg, but no grade 4 or 5 side effects were seen at 60mg, and there were no dose reductions or discontinuations due to side effects. Five out of five patients who had a complete response, which means their disease was no longer detectable, after three months, were still in complete response after six months, with the first participant still in complete response after 12 months and still on the drug after 14 months. In the SURF303 study, the first patient had a complete response after three months, with an N1 classification, which refers to the presence of cancer in nearby lymph nodes. The exposure threshold of 2500 ng.hr/mL was used to measure the effectiveness of the treatment, and the overall response rate was 12 out of 14 patients above this threshold, compared to 7 out of 12 patients below it, although this comparison is exploratory and not randomized. https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib

The primary sponsor of the issuer reported on September 9 that there were 44 safety participants, with 22 participants each taking 50mg and 60mg. After at least 3 months of assessment, 26 participants were evaluated for efficacy, with 14 taking 60mg and 12 taking 50mg. The overall response rate, or ORR, for the 60mg group after 3 months was 11 out of 14, with 8 out of 14 having a complete response, or CR. The best CR was 9 out of 14. For the 50mg group, the ORR was 8 out of 12, with 4 out of 12 having a CR. A subgroup of 8 participants taking 60mg with a single marker had an ORR of 8 out of 8, with 5 out of 8 having a CR after 3 months, and 6 out of 8 having the best CR. For all doses with a single marker, which is a term that refers to a specific indicator used to measure the effectiveness of a treatment, 16 participants were evaluated, with an ORR of 15 out of 16, 8 out of 16 having a CR after 3 months, and 9 out of 16 having the best CR. The evaluation was restricted to certain participants, and the remaining 18 participants were not automatically considered failures, with ITT meaning intent to treat, which is a method of analyzing data where all participants are included, regardless of whether they completed the treatment or not. https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib

A computer program using Python recalculated a past test called savedbacktest456, using no new data. The test had 17 wins out of 41, with an average win of 5.46270406% and an average loss of 2.96357664%. The mean point was 0.530247%, the breakeven point was 35.1706375%, and the raw quarter Kelly was 2.42666937%. No trades were approved because the mean confidence interval was between -0.874362% and 1.958541%. In a live test, 2 out of 2 trades were successful, with a Wilson 95% confidence interval of 34.2380% to 100%, even assuming independent and identically distributed data, and there were no empirical losses on average. This was not an independent validation. https://runway.adityaperswal.workers.dev/data/stock-bars

On September 9, before the market opened, the account had $850.99 in cash and $278.67 in supply. A check of the supply trades, also known as a query of trades, showed no open or pending trades, but it did show two closed trades that were ended by the operator. These trades were not planned to be closed at that time. A note from job 116, which was written at 12:30:52, mentioned that an attempt was made to end something, but there was an error with CENTCOM and a challenge with Bombardier. Jobs 12, 18, 36, 73, and 116 still exist, and none of them are eligible to be closed. https://runway.adityaperswal.workers.dev

On September 8, the issuer released a press release, PR119, which mentioned that they expect to produce liquid helium and start shipping stable isotopes, with a goal of making over 300 million in EBITDA by 2031. However, there are no verified records of accepted payments for helium or liquefied natural gas in September. A replay of the CMD is available, but the link to the replay requires registration and does not include a transcript of the question and answer session, which is still missing. The latest press release, PR119, is available through an RSS feed for collectors. https://ir.aspisotopes.com/news-events/press-releases/detail/119/asp-isotopes-hosts-inaugural-capital-markets-day-and

A news scan found the headline 'FRO CENTCOM original report recovered despite collector error'. On September 8, a first-party belligerent statement was re-read on September 9, claiming that five tankers were struck on September 8 and three on September 5. The statement does not provide numbers for independent replacement fixtures, insurance payments, or profitable FRO receipts. The original report is accessible manually, but this does not imply independent confirmation. https://www.centcom.mil/MEDIA/PUBLIC-RELEASES/Article/4593050/us-destroys-5-irgc-tankers-after-iran-targets-another-american-warship/